Osteosarcoma is the most common pediatric primary bone tumor worldwide and is associated with a high metastatic rate and poor prognosis. Initially, survivals were marginally improved over surgery alone with the introduction of chemotherapy. But survivals have not further improved in recent decades. Overall survival rate in the human population is only 30%. New therapies for this disease are desperately needed. Canine Osteosarcoma shares many common molecular pathways with human osteosarcoma and is an attractive model for comparative research.
This webinar will provide a brief summary of conventional treatment options and associated prognosis for canine appendicular osteosarcoma and introduce western biomedical evidence supporting potential benefits of Traditional Chinese Medicine (TCM) herbal therapy in patient care. In particular, preliminary results of a clinical trial run at the author’s practice using TCM herbal medicine in the palliative care setting will be presented. This information is presented with the vision of beginning to bridge the gap that is often present between these treatment approaches. Improved communication between “conventional” and “alternative” medicine approaches can benefit patient care and assist practitioners in advising clients regarding potential diagnostic and treatment options that may be desired or beneficial to improving patient outcome.